Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG)

Efstathios Kastritis; Eirini Katodritou; Sorina Bădeliță; Jelena Bila; Güldane Cengiz Seval; Zorica Cvetković; Daniel Coriu; Emmanouil Spanoudakis; Dimitra Dalampira; Aleksandra Sretenović; Aggeliki Sevastoudi; Anca Bojan; Catalin Danaı̈la; Maria Gavriatopoulou; Μαρία Ρούσσου; Charalampos Charalampous; Evangelos Terpos; Meral Beksac; Meletios Α. Dimopoulos

doi:10.1080/10428194.2024.2391900

Abstract

Multiple myeloma (MM) patients exhibit heterogeneous outcomes, necessitating reliable prognostic tools to guide treatment. In 2015, the Revised International Staging System (R-ISS) was developed to...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kastritis et al. (2024) studied this question.

synapsesocial.com/papers/6a8807b36304c7fd8e4ded89 https://doi.org/10.1080/10428194.2024.2391900

View at Publisher

Ask AI

Bookmark

Share

Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG)

Abstract

Discussion

Cite This Study

Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG)

Abstract

Discussion

Cite This Study

Keep reading

Keep reading